Recent News

• 08.12.2025 - NeurAxis Second Quarter 2025 Earnings Conference Call
• 08.12.2025 - NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
• 08.05.2025 - NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
• 06.17.2025 - NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
• 06.17.2025 - NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
• 06.10.2025 - NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
• 05.27.2025 - NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
• 05.27.2025 - NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
• 05.22.2025 - NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
• 05.22.2025 - NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

Recent Filings

• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 8-K Current report
• 07.02.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.01.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.04.2025 - 8-K Current report
• 05.28.2025 - 8-K Current report
• 05.28.2025 - EX-99.1 EX-99.1
• 05.22.2025 - 8-K Current report